Sugi Predict

Sugi Predict / Targets / KAT8

KAT8

Histone acetyltransferase KAT8 · Q9H7Z6 · KAT8 on Sugi Atlas →

46,481 patent compounds predicted against KAT8, 21,702 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL278723 SCHEMBL278723 0.56 9/20
SCHEMBL278669 SCHEMBL278669 0.51 8/20
SCHEMBL245318 SCHEMBL245318 0.64 6/20
SCHEMBL245319 SCHEMBL245319 0.64 6/20
SCHEMBL231918 SCHEMBL231918 0.57 5/20
SCHEMBL166504 SCHEMBL166504 0.51 5/20
SCHEMBL289432 SCHEMBL289432 0.50 5/20
SCHEMBL39502 SCHEMBL39502 0.43 5/20
Anacardic Acid Anacardic Acid (SCHEMBL154720) 1.00 4/20
SCHEMBL367092 SCHEMBL367092 1.00 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL295131) 0.95 4/20
Gingkolic Acid Gingkolic Acid (SCHEMBL163525) 0.84 4/20
SCHEMBL154719 SCHEMBL154719 0.77 4/20
SCHEMBL290916 SCHEMBL290916 0.55 4/20
SCHEMBL19866 SCHEMBL19866 0.54 4/20
SCHEMBL22849 SCHEMBL22849 0.54 4/20
SCHEMBL76099 SCHEMBL76099 0.54 4/20
SCHEMBL180856 SCHEMBL180856 0.54 4/20
SCHEMBL183977 SCHEMBL183977 0.54 4/20
SCHEMBL208349 SCHEMBL208349 0.54 4/20

Clinical trials — most relevant to KAT8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Research In Viral Eradication of HIV Reservoirs PHASE2COMPLETED
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study nanNOT_YET_RECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KAT8 binder may also engage these)

ProteinNameSimilarity
Q5XI06 — 1.000 Q5XI06 →
Q9D1P2 — 1.000 Q9D1P2 →
Q9TYU5 — 1.000 Q9TYU5 →
Q6C710 — 1.000 Q6C710 →
Q9LXD7 — 1.000 Q9LXD7 →
Q8LI34 — 1.000 Q8LI34 →
Q7S9B6 — 1.000 Q7S9B6 →
Q99MK2 — 1.000 Q99MK2 →
Q6CKE9 — 0.999 Q6CKE9 →
KAT5 Histone acetyltransferase KAT5 0.998 landscape →
DHX29 ATP-dependent RNA helicase DHX29 0.998 landscape →
KDM5D Lysine-specific demethylase 5D 0.997 landscape →
Q5SVQ0 — 0.997 Q5SVQ0 →
Q9FLF7 — 0.997 Q9FLF7 →
Q6FPH9 — 0.997 Q6FPH9 →
Q8CHK4 — 0.997 Q8CHK4 →
D3ZA12 — 0.997 D3ZA12 →
Q810T5 — 0.997 Q810T5 →
Q5XUN4 — 0.996 Q5XUN4 →
Q5F3R2 — 0.996 Q5F3R2 →
C8VBH4 — 0.996 C8VBH4 →
Q75BY2 — 0.996 Q75BY2 →
Q61T02 — 0.996 Q61T02 →
O94446 — 0.996 O94446 →
P41230 — 0.996 P41230 →
P25799 — 0.996 P25799 →
Q8BX57 — 0.996 Q8BX57 →
Q8WUF8 — 0.996 Q8WUF8 →
A3KMI0 — 0.995 A3KMI0 →
Q80Y84 — 0.995 Q80Y84 →